<DOC>
	<DOCNO>NCT02919462</DOCNO>
	<brief_summary>This open-label , multicentre , randomize phase II trial . Eligible patient Non Small Cell Lung Cancer ( NSCLC ) high Thymidylate Synthase ( TS ) expression , randomly assign 1:1 ratio follow treatment Arms : A . 4 cycle Cisplatin + Oral Vinorelbine follow maintenance Metronomic Oral Vinorelbine disease progression B . 4 cycle Cisplatin + Pemetrexed follow maintenance Pemetrexed disease progression Treatment repeat every 21 day .</brief_summary>
	<brief_title>Open-label , Multicenter , Randomized Phase II Trial Treatment With Cisplatin Pemetrexed Cisplatin Oral Vinorelbine Chemotherapy Naïve Patients Affected Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer With High Thymidylate Synthase Expression</brief_title>
	<detailed_description>An Open-label , Multicenter , Randomized Phase II Trial Treatment Cisplatin Pemetrexed Cisplatin Oral Vinorelbine Chemotherapy Naïve Patients affect stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer high Thymidylate Synthase ( TS ) expression After sign informed consent TS expression evaluation ( see Appendix A ) , patient test TS expression status tumor tissue . If TS expression 70 nucleus ≥210 nucleus cytoplasm tumor cell , categorize high TS expression patient , less , consider TS-negative . Study Treatment : Eligible patient randomly assign follow treatment Arms : A . Oral vinorelbine 60-80 mg/m2 day 1 8 ( first cycle 60 mg/m2 ) + Cisplatin 80 mg/m2 day 1 every 3 week , 4 cycle . Maintenance Metronomic Oral Vinorelbine 50 mg three time week Monday , Wednesday Friday continuously disease progression , patient refusal excessive toxicity ( 1 cycle : 3 week ) . B. Pemetrexed , 500 mg/m2 , day 1 + Cisplatin , 75 mg/m2 , day 1 every 3 week , 4 cycle . Maintenance Pemetrexed 500 mg/m2 day1 q 21 disease progression ( 1 cycle : 3 week ) . 7-10 day treatment administration , premedication vitamin B12 1000µg intramuscular injection ( every 9 week ) folate 1mg every day commence . The total duration study 3 year . The enrollment period wil 2 year 1 year follow . Treatment period : disease progression , intolerable toxicity patient refusal . Number Subjects :130 patient ( 65 patient per arm ) Statistical Methodology The primary variable study Disease Control Rate ( DCR ) . According primary variable , assume DCR≥70 % patient high TS expression treat cisplatin vinorelbine DCR=44 % patient high TS expression treat cisplatin pemetrexed , consider 2-tailed alpha=0.05 beta=0.10 , necessary enroll 65 patient per arm ( 130 patient total ) 24-month period subsequent 12-month follow-up .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients must histologically cytologically Nonsquamous NSCLC , ( include nonspecified tumor type ) . 2 . Metastatic ( stage IV , M1A M1B ) locally advanced ( stage IIIB , metastasis supraclavicular node ) accord TNM VII edition . 3 . TS nuclear Hscore ≥ 70 TS nuclear cytoplasmatic Hscore ≥ 210 . 4 . Patients first diagnosis disease recurrence former surgery eligible . 5 . Patients must measurable disease , define least one lesion accurately measure least one dimension ( long diameter record ) ≥20 mm conventional technique ≥10 mm spiral CT scan . See section 9.2 Appendix E evaluation measurable disease . 6 . At least one target nontarget lesion previously irradiate accord RECIST version 1.1 7 . Male Female , age ≥18 year . 8 . Life expectancy great 3 month . 9 . ECOG performance status ≤2 ( see Appendix C ) . 10 . Patients must normal organ marrow function define : leukocyte ≥3,000/µL absolute neutrophil count ≥1,000µL platelets ≥100,000/µL total bilirubin within normal institutional limit AST ( SGOT ) /ALT ( SGPT ) ≤2.5 X institutional upper limit normal creatinine within normal institutional limit OR creatinine clearance ≥60 mL/min/1.73 m2 patient creatinine level institutional normal 11 . Female participant child bear potential male participant whose partner child bear potential must willing ensure partner use effective contraception study 3 month thereafter 12 . Participant willing able give inform consent participation study . 1 . Prior chemotherapy therapy systemic antineoplastic therapy advance disease . 2 . Prior surgery and/or localise irradiation permit delivered outside target lesion . 3 . Prior adjuvant chemotherapy permit contain vinorelbine pemetrexed administer least 6 month prior enter study . 4 . Participation another clinical trial investigational agent within 30 day prior study screen . 5 . Patients symptomatic brain metastasis spinal cord compression yet treat surgery and/or radiation . Patients CNS metastasis spinal cord compression previously treat surgery and/or radiation eligible asymptomatic require escalate high dose steroid ( antiseizure medication allow ) 6 . History allergic reaction attribute compound similar chemical biologic composition pemetrexed , vinorelbine , cisplatin , carboplatin agent use study . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . 8 . Other know malignant neoplastic disease patient 's medical history diseasefree interval le 5 year ( except previously treat basal cell carcinoma situ carcinoma uterine cervix surgically resected prostate cancer normal PSA ) ; 9 . NSCLC EGFR mutation ( able use EGFR inhibitor ) anaplastic lymphoma kinase ( ALK ) gene translocation ( EML4ALK ) . 10 . Has know allergy , hypersensitivity , contraindication cisplatin , pemetrexed , vinorelbine component use preparation contraindication specify section 7 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Carcinoma , Non-Small-Cell Lung</keyword>
	<keyword>advanced stage IIIB</keyword>
	<keyword>high Thymidylate Synthase expression</keyword>
	<keyword>Treatment</keyword>
	<keyword>Chemotherapy Naïve Patients</keyword>
	<keyword>stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer</keyword>
	<keyword>Cisplatin Pemetrexed</keyword>
	<keyword>Cisplatin Oral Vinorelbine</keyword>
</DOC>